title: The evolving experience using everolimus in clinical transplantation.
abstract: Everolimus is a derivative of sirolimus, a macrocyclic lactone, originally isolated from Streptomyces hygroscopicus. Both everolimus and sirolimus have a similar mechanism of action, exerting potent inhibition of growth factor-induced proliferation of lymphocytes, as well as other hematopoietic and nonhematopoietic cells of mesenchymal origin. Each agent complexes with the FK506 binding protein 12 to inhibit cyclin dependent kinase(s), collectively termed the target of rapamycin (TOR), causing G1-S phase cell cycle arrest. Safety and efficacy have been documented in large-scale, blinded, randomized, international clinical renal and cardiac transplant trials. Everolimus is more hydrophilic, exhibits a shorter elimination half-life (approximately 30 hours), and demonstrates greater relative bioavailability compared to sirolimus. However, similar to the calcineurin inhibitors and sirolimus, everolimus is biotransformed by the cytochrome P450, 3A4 isozyme. Also similar to sirolimus, clinical experiences identified biologically relevant side effects including hyperlipidemia and exacerbation of cyclosporine (CsA)-associated nephrotoxicity. However, also similar to sirolimus, accumulating evidence suggests that the hyperlipidemia can be controlled and the CsA-associated renal effects appear reduced with a low incidence of acute rejection when everolimus is administered in combination with reduced CsA doses. The experience using everolimus in cardiac transplantation has also provided potentially important insights into the consequences of antiproliferative effects on vascular smooth muscle cells and fibroblasts where reduction in intimal expansion was identified by intravascular coronary ultrasound examination among those patients receiving everolimus. Therefore, available results suggest that the introduction of everolimus as the newest TOR inhibitor should enhance therapeutic options for immunosuppression after organ transplantation.
authors.affiliation: Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, CT 06520, USA.
authors.forename: R N
authors.initials: RN
authors.lastname: Formica
authors.forename: K M
authors.initials: KM
authors.lastname: Lorber
authors.forename: A L
authors.initials: AL
authors.lastname: Friedman
authors.forename: M J
authors.initials: MJ
authors.lastname: Bia
authors.forename: F
authors.initials: F
authors.lastname: Lakkis
authors.forename: J D
authors.initials: JD
authors.lastname: Smith
authors.forename: M I
authors.initials: MI
authors.lastname: Lorber
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use* / Q000633:toxicity; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use* / Q000633:toxicity; D014181:Transplantation Immunology
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus